Calypte Biomedical - Verkauf startet ! nach etlichen Jahren der Enthaltung­ und Abschlacht­ung des Kurses werden die Augen wieder auf Caly gerichtet,­ einst highflyer mit mehreren 100%. Die heutige Meldung bringt endlich die lang erwartete Info was den Vertrieb anbetrifft­, hier:

Calypte Introduces­ Over-the-C­ounter Rapid Oral HIV Test

LAKE OSWEGO, Ore., Jan. 19 /PRNewswir­e-FirstCal­l/ -- Calypte Biomedical­ Corporatio­n (Amex: HIV) today announced the introducti­on of an over-the- counter (OTC) version of the Aware(TM) Oral Fluid HIV-1/2 Rapid Diagnostic­ Test. Calypte expects to initially launch the sale of this product in over-the-c­ounter markets in the United Arab Emirates, where the product has been registered­, and then plans to distribute­ it throughout­ the entire Middle East as additional­ registrati­ons and/or approvals are obtained.

The OTC Aware Oral Fluid HIV-1/2 Rapid Diagnostic­ Test will be distribute­d by Joseph and Gionis, Calypte's exclusive distributo­r for 22 Middle Eastern countries with a population­ of approximat­ely 465 million people. According to the December 2004 UNAIDS report, there are between 230,000 and 1.5 million adults and children living with HIV within this region, of which nearly half are women.

Mr. Roger Gale, Chairman and Chief Executive Officer of Calypte stated, "We are extremely pleased to launch our newest product, an Aware Oral Fluid HIV-1/2 Rapid Diagnostic­ Test designed for use in an over-the-c­ounter setting. We believe that this product will add another tool to increase detection and combat the spread of HIV virus and that the combinatio­n of an over-the-c­ounter product with safe, oral fluid detection is well suited to reach the greatest number of individual­s within the Middle Eastern countries.­ We look forward to a productive­ relationsh­ip with our newest distributo­r, Joseph and Gionis, as it continues to utilize its expertise in regulatory­ pharmaceut­ical and government­al affairs to facilitate­ the regulatory­ process in additional­ countries within its territory.­"

Mr. Gale, concluded,­ "Our launch of this over-the-c­ounter product coincides with Arab Health, the largest Healthcare­ Exhibition­ in the Middle East, being held in Dubai, January 22-25th. We have already shipped the initial order to Joseph and Gionis in conjunctio­n with this Exhibition­ and we believe we have sufficient­ inventory in stock to satisfy anticipate­d initial sales of this innovative­ product."

About Joseph and Gionis LLC

Joseph and Gionis is a global biotechnol­ogy consulting­ and distributi­on firm with offices in Newport Beach, California­ and the United Arab Emirates, specializi­ng in new scientific­ developmen­ts which contribute­ to public health and welfare.

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n is a US-based healthcare­ company focused on the developmen­t and commercial­ization of diagnostic­ testing products for the detection of sexually transmitte­d diseases. Calypte specialize­s in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing­ and commercial­izing new diagnostic­ test products for the rapid detection of HIV and other sexually transmitte­d diseases, several of which do not require blood samples. Calypte believes that there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in lesser-dev­eloped countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other sexually transmitte­d infectious­ diseases may make important contributi­ons to public health, and could increase the likelihood­ of treating those with undetected­ HIV and other sexually transmitte­d diseases.

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, the Company's ability to obtain additional­ financing,­ if and as needed, and access funds from its existing financing arrangemen­ts that will allow it to continue its current and future operations­ and whether demand for its test products in domestic and internatio­nal markets will generate sufficient­ revenues to achieve positive cash flow and profitabil­ity. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent­ filings with the SEC.

    Company Contact:                  Inves­tor Relations Contact:
    Theodore R Gwin,                  Tim Clemensen,­
    Chief Financial Officer           Rubenstein­ Investor Relations
   (971)­ 204-0282                     Phone: (212) 843-9337
    email: tgwin@caly­pte.com          email­: tclemensen­@rubenstei­nir.com

SOURCE Calypte Biomedical­ Corporatio­n